Trial Profile
MABp1 [XILONIX] in patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2015
Price :
$35
*
At a glance
- Drugs Bermekimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Apr 2015 Positive results from subset of patients are published in Investigational New Drugs journal and are available online, according to XBiotech company media release.
- 22 May 2013 New trial record